JP2011511622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511622A5 JP2011511622A5 JP2010541803A JP2010541803A JP2011511622A5 JP 2011511622 A5 JP2011511622 A5 JP 2011511622A5 JP 2010541803 A JP2010541803 A JP 2010541803A JP 2010541803 A JP2010541803 A JP 2010541803A JP 2011511622 A5 JP2011511622 A5 JP 2011511622A5
- Authority
- JP
- Japan
- Prior art keywords
- qpct
- human animal
- mouse
- model
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims 12
- 101150035356 Qpct gene Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 241000699666 Mus <mouse, genus> Species 0.000 claims 8
- 238000010171 animal model Methods 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000012216 screening Methods 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 241001323319 Psen Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims 2
- 238000013279 ApoE knockout mouse model Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700024394 Exon Proteins 0.000 claims 1
- 208000009386 Experimental Arthritis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011552 rat model Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2078408P | 2008-01-14 | 2008-01-14 | |
| PCT/EP2009/050387 WO2009090190A1 (en) | 2008-01-14 | 2009-01-14 | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011511622A JP2011511622A (ja) | 2011-04-14 |
| JP2011511622A5 true JP2011511622A5 (https=) | 2012-03-01 |
Family
ID=40427980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541803A Pending JP2011511622A (ja) | 2008-01-14 | 2009-01-14 | グルタミニルシクラーゼ遺伝子のノックアウト変異を有するマウスモデル |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9462793B2 (https=) |
| EP (1) | EP2238252B1 (https=) |
| JP (1) | JP2011511622A (https=) |
| AU (1) | AU2009204864A1 (https=) |
| CA (1) | CA2710494A1 (https=) |
| IL (1) | IL206484A0 (https=) |
| NZ (1) | NZ586665A (https=) |
| WO (1) | WO2009090190A1 (https=) |
| ZA (1) | ZA201004367B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015296135A1 (en) | 2014-08-01 | 2017-02-16 | The Johns Hopkins University | MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| US20030013177A1 (en) * | 2001-05-23 | 2003-01-16 | Ebens Allen J. | Polynucleotides encoding insect glutaminyl cyclase and uses thereof |
| US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| EP1961416B1 (en) | 2003-05-05 | 2013-01-23 | Probiodrug AG | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. |
| CN1784220B (zh) | 2003-05-05 | 2011-08-03 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
| US8338120B2 (en) | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
| BRPI0415409A (pt) | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US20050171112A1 (en) | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CA2554809C (en) | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| EA016584B1 (ru) | 2006-09-21 | 2012-06-29 | Пробиодруг Аг | Новые гены, родственные гену глутаминилциклазы |
| ES2481442T3 (es) | 2006-11-09 | 2014-07-30 | Probiodrug Ag | Inhibidores novedosos de glutaminil ciclasa |
| US8420684B2 (en) | 2006-11-09 | 2013-04-16 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| WO2008087197A1 (en) * | 2007-01-19 | 2008-07-24 | Probiodrug Ag | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
| JP5612860B2 (ja) | 2007-03-09 | 2014-10-22 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体 |
| DK2160389T3 (da) | 2007-04-18 | 2014-06-23 | Probiodrug Ag | Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| ES2468551T3 (es) | 2007-04-18 | 2014-06-16 | Probiodrug Ag | Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa |
| WO2008128986A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
| ES2473621T3 (es) | 2007-04-18 | 2014-07-07 | Probiodrug Ag | Derivados de nitrovinil-diamina como inhibidores de glutaminil ciclasa |
| EP2160380B1 (en) | 2007-04-18 | 2014-04-02 | Probiodrug AG | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
| WO2008128984A1 (en) | 2007-04-20 | 2008-10-30 | Probiodrug Ag | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
| AU2008297070A1 (en) | 2007-09-12 | 2009-03-19 | Probiodrug Ag | Transgenic mice |
-
2009
- 2009-01-14 WO PCT/EP2009/050387 patent/WO2009090190A1/en not_active Ceased
- 2009-01-14 CA CA2710494A patent/CA2710494A1/en not_active Abandoned
- 2009-01-14 AU AU2009204864A patent/AU2009204864A1/en not_active Abandoned
- 2009-01-14 NZ NZ586665A patent/NZ586665A/en not_active IP Right Cessation
- 2009-01-14 EP EP09702062.2A patent/EP2238252B1/en not_active Not-in-force
- 2009-01-14 JP JP2010541803A patent/JP2011511622A/ja active Pending
- 2009-01-14 US US12/353,463 patent/US9462793B2/en not_active Expired - Fee Related
-
2010
- 2010-06-20 IL IL206484A patent/IL206484A0/en unknown
- 2010-06-21 ZA ZA2010/04367A patent/ZA201004367B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501652A5 (https=) | ||
| Alenina et al. | ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models | |
| Schinke et al. | Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen | |
| Kusche-Vihrog et al. | Salt controls endothelial and vascular phenotype | |
| Patel et al. | From gene to protein—experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension | |
| Caravia et al. | The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function | |
| Dao et al. | Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans | |
| Asselbergs et al. | Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci | |
| Yamada et al. | Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain | |
| Fatscher et al. | Mechanism, factors, and physiological role of nonsense-mediated mRNA decay | |
| Tunquist et al. | Loss of AKAP150 perturbs distinct neuronal processes in mice | |
| Kapoor et al. | An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval | |
| Patrakka et al. | Nephrin–a unique structural and signaling protein of the kidney filter | |
| Takaluoma et al. | Tissue-specific changes in the hydroxylysine content and cross-links of collagens and alterations in fibril morphology in lysyl hydroxylase 1 knock-out mice | |
| Hu et al. | Mesenchymal deficiency of Notch1 attenuates bleomycin-induced pulmonary fibrosis | |
| JP2015523863A5 (https=) | ||
| JP2010516235A5 (https=) | ||
| Park et al. | Deficits in Col5a2 expression result in novel skin and adipose abnormalities and predisposition to aortic aneurysms and dissections | |
| Duverger et al. | In vivo impact of Dlx3 conditional inactivation in neural crest‐derived craniofacial bones | |
| Paone et al. | Genetics of cardiovascular disease: fishing for causality | |
| AU2019392679A1 (en) | Methods of detecting, preventing, reversing, and treating neurological diseases | |
| Drexel et al. | Neuron type-specific miRNA represses two broadly expressed genes to modulate an avoidance behavior in C. elegans | |
| O'Callaghan et al. | Central angiotensinergic mechanisms associated with hypertension | |
| Charton et al. | Removal of the calpain 3 protease reverses the myopathology in a mouse model for titinopathies | |
| Schilling et al. | Glutaminyl cyclase knock-out mice exhibit slight hypothyroidism but no hypogonadism: implications for enzyme function and drug development |